Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357088 | 0.96 | MAP3K5 (0.35) | DHODHMAP3K5P2RX3P2RX2 | |
| SCHEMBL358747 | 0.94 | DHODH (0.36) | DHODHMAP3K5P2RX3P2RX2 | |
| SCHEMBL16547254 | 0.83 | LMNA (0.38) | MAP3K5P2RX3P2RX2 | |
| SCHEMBL357410 | 0.82 | P2RX3 (0.48) | P2RX3P2RX2 | |
| SCHEMBL16875773 | 0.80 | LMNA (0.40) | MAP3K5P2RX3P2RX2 | |
| SCHEMBL359386 | 0.78 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL358473 | 0.78 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL357541 | 0.78 | P2RX3 (0.49) | P2RX3P2RX2 | |
| SCHEMBL10225851 | 0.75 | ALDH1A1 (0.34) | MAP3K5 | |
| SCHEMBL368767 | 0.72 | P2RX3 (0.48) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234989-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077371-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |